Compare iShares US Power Infrastructure ETF (POWR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares US Power Infrastructure ETF vs Tango Therapeutics Inc. — how do they compare? iShares US Power Infrastructure ETF trades at $24.99 (market cap $448.01M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 8.4× iShares US Power Infrastructure ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Power Infrastructure ETF for 19 Days and Tango Therapeutics Inc. for 0 Days on average.
| POWR | TNGX | |
|---|---|---|
Market Cap | $448.01M | $3.75B |
Volume | 115,109 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $28.22 | $32.90 |
52-Week Low | $23.20 | $7.50 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares US Power Infrastructure ETF
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
